Development and Validation of a Clinical Risk Score to Predict Immune-mediated Liver Injury Caused by Sintilimab: Assessed for Causality Using Updated RUCAM.

Caiyun Zheng Shunmin Huang Meimei Lin Baohui Hong Hengfen Dai Jing Yang

Published in: Journal of clinical and translational hepatology (2023)

This study demonstrated that hypoproteinemia, dyslipidemia, and the presence of thyroid peroxidase antibodies were clinically feasible prognostic biomarkers to predict liver injury in patients treated with sintilimab.

Keyphrases

liver injury
drug induced
adverse drug
hydrogen peroxide
nitric oxide